*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Diabetes, obesity & metabolism · preclinical | PMID 41090431 |
| 2025 | Retatrutide-A Game Changer in Obesity Pharmacotherapy Biomolecules · preclinical | PMID 40563436 |
| 2025 | Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial The lancet. Diabetes & endocrinology · human | PMID 40609566 |
| 2025 | Emerging pharmacotherapies for obesity: A systematic review Pharmacological reviews · preclinical | PMID 39952695 |
| 2025 | What is the pipeline for future medications for obesity? International journal of obesity (2005) · preclinical | PMID 38302593 |
| 2025 | Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials Journal of basic and clinical physiology and pharmacology · preclinical | PMID 40728138 |
| 2024 | Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity Diabetes care · preclinical | PMID 38843460 |
| 2024 | Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Nature medicine · human | PMID 38858523 |
| 2024 | The power of three: Retatrutide's role in modern obesity and diabetes therapy European journal of pharmacology · preclinical | PMID 39515565 |
| 2024 | Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes care · preclinical | PMID 38687506 |
| 2024 | Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials Metabolism open · preclinical | PMID 39318607 |
| 2024 | Gut hormones and appetite regulation Current opinion in endocrinology, diabetes, and obesity · preclinical | PMID 38511400 |
| 2024 | Retatrutide Clinical diabetes : a publication of the American Diabetes Association · preclinical | PMID 39429457 |
| 2023 | Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial The New England journal of medicine · human | PMID 37366315 |
| 2023 | Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Lancet (London, England) · human | PMID 37385280 |
Retatrutide (Retatrutide (GIP/GLP-1/glucagon triple agonist)). Triple receptor agonist (GIP, GLP-1, glucagon). Adds glucagon-receptor agonism to increase energy expenditure alongside appetite reduction and improved glycaemic control.
Commonly discussed uses: investigational: obesity, type 2 diabetes (clinical trials). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Triple receptor agonist (GIP, GLP-1, glucagon). Adds glucagon-receptor agonism to increase energy expenditure alongside appetite reduction and improved glycaemic control.
Reported considerations: GI: nausea, vomiting, diarrhoea (dose-related in trials), long-term safety unknown. There is both human and animal/preclinical research, though the depth and quality vary by indication. INVESTIGATIONAL ONLY. Not approved anywhere. Grey-market sale as 'research peptide' is unverified material. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low trial titration (1-2mg), typical investigational, high up to 12mg/week in trials. Administration: subcutaneous. Half-life: ~6 days (reported).
Australian status: Investigational — not approved/registered. INVESTIGATIONAL ONLY. Not approved anywhere. Grey-market sale as 'research peptide' is unverified material. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research vials vary; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): investigational monotherapy in trials. Stacking increases interaction/safety uncertainty.